Detalhe da pesquisa
1.
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.
Nature
; 615(7954): 920-924, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36922593
2.
Therapy-related acute lymphoblastic leukaemia in women with antecedent breast cancer.
Br J Haematol
; 2024 Mar 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38556836
3.
The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis.
Blood
; 140(20): 2101-2112, 2022 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35877996
4.
Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia.
Blood
; 139(24): 3519-3531, 2022 06 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35192684
5.
A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant.
Haematologica
; 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38328852
6.
Optimizing CAR-T cell therapy in adults with B-cell acute lymphoblastic leukemia.
Eur J Haematol
; 112(2): 236-247, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37772976
7.
Important Considerations in the Intensive Care Management of Acute Leukemias.
J Intensive Care Med
; 39(4): 291-305, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37990559
8.
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
JAMA
; 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38722621
9.
Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL.
Blood
; 137(4): 471-484, 2021 01 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32881995
10.
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia.
Blood
; 137(6): 751-762, 2021 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32929488
11.
Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
Am J Hematol
; 98(4): 666-680, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36691748
12.
Hematopoietic stem cell donor vaccination with cytomegalovirus triplex augments frequencies of functional and durable cytomegalovirus-specific T cells in the recipient: A novel strategy to limit antiviral prophylaxis.
Am J Hematol
; 98(4): 588-597, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36594185
13.
High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions.
Am J Hematol
; 98(6): 848-856, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36880203
14.
Asparaginase: How to Better Manage Toxicities in Adults.
Curr Oncol Rep
; 25(1): 51-61, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36449117
15.
Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia.
Cancer
; 128(3): 529-535, 2022 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34633671
16.
How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia.
Blood
; 135(13): 987-995, 2020 03 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31977001
17.
How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy.
Blood
; 135(11): 804-813, 2020 03 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31899793
18.
Immunophenotype of acute lymphoblastic leukemia in minorities- analysis from the SEER database.
Hematol Oncol
; 40(1): 105-110, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34766363
19.
A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia.
Cancer
; 127(16): 2943-2953, 2021 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33934351
20.
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
Cancer
; 127(7): 1039-1048, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33259056